Today
+1.36%
5 Days
+7.32%
1 Month
-12.49%
6 Months
-22.40%
Year to Date
-33.12%
1 Year
-20.10%
• Stryker exceeded second-quarter earnings expectations across MedSurg and Neurotechnology segments. • Management raised full-year earnings guidance citing operational efficiencies and market share gains. • Analysts maintain a Buy rating with an average price target of $385.60.
• Quarterly procedure volume growth exceeded expectations, driving the company’s recent valuation increase. • Adoption of robotic platforms and AI integration supports recurring revenue and surgical precision. • Intuitive Surgical reports $10.06 billion in annual revenue with high institutional investor support.
• Intuitive Surgical exceeded quarterly expectations, raising full-year guidance on high global procedure volumes. • Strong Da Vinci 5 platform adoption and recurring revenue streams drove institutional investor confidence. • Technical indicators show a sell signal, despite positive fundamental growth and market positioning.
• Stryker exceeded second-quarter earnings expectations driven by strong MedSurg and Neurotechnology segment performance. • Management raised full-year organic growth and earnings guidance following higher elective procedure volumes. • Analyst upgrades and increased institutional demand contributed to positive momentum in Stryker shares.
• Thermo Fisher Q2 2026 results exceeded expectations amid bioprocessing recovery and inventory normalization. • Management raised full-year earnings guidance following strong growth in clinical research and diagnostics. • Analysts issued multiple buy ratings with an average price target of $603.15.
• UnitedHealth reported strong quarterly earnings driven by growth in its Optum health services segment. • Stable Medicare Advantage reimbursement rates have improved sentiment toward the managed care sector. • A resilient labor market and cooling inflation are supporting UnitedHealth's commercial insurance revenue.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.52% |
| BlackRock Institutional Trust Company, N.A. | 5.32% |
| State Street Investment Management (US) | 4.43% |
| T. Rowe Price Associates, Inc. | 3.40% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 50.32% |
| Investment Advisor/Hedge Fund | 26.27% |
| Hedge Fund | 3.22% |
| Pension Fund | 2.76% |
Related Instruments
Popular Instruments